These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 16622122)

  • 41. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol.
    Nicolaiew N; Ploussard G; Chun FK; Xylinas E; Allory Y; Salomon L; de la Taille A
    Urol Int; 2013; 90(3):306-11. PubMed ID: 23295308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate cancer risk prediction in a urology clinic in Mexico.
    Liang Y; Messer JC; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Oncol; 2013 Oct; 31(7):1085-92. PubMed ID: 22306115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
    Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.
    Reed A; Ankerst DP; Pollock BH; Thompson IM; Parekh DJ
    J Urol; 2007 Nov; 178(5):1929-32; discussion 1932. PubMed ID: 17868724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
    Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
    J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
    Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
    West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are prostatic biopsies necessary in men aged > or =80 years?
    Bott SR; Foley CL; Bull MD; Reddy CC; Freeman A; Montgomery BS; Langley SE
    BJU Int; 2007 Feb; 99(2):335-8. PubMed ID: 17326264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
    Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy.
    Park SJ; Miyake H; Hara I; Eto H
    Int J Urol; 2003 Feb; 10(2):68-71. PubMed ID: 12588600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating possible predictors of prostate cancer to establish a scoring system for repeat biopsies in Chinese men.
    Xu B; Min Z; Cheng G; Mi Y; Tong N; Feng N; Song N; Zhang W; Wu H; Zhang Z; Wang Z; Hua L
    J Ultrasound Med; 2011 Apr; 30(4):503-8. PubMed ID: 21460150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
    van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH
    BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
    Cao XL; Gao JP; Han G; Tang J; Hong BF
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer screening parameters in a high-risk African-Caribbean population.
    Bunker CH; Patrick AL; Miljkovic-Gacic I; Konety BR; Belle A; Richard JR; Dhir R
    Urology; 2004 Apr; 63(4):737-41. PubMed ID: 15072891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.